WO2021210636A1 - 乳がん治療剤 - Google Patents
乳がん治療剤 Download PDFInfo
- Publication number
- WO2021210636A1 WO2021210636A1 PCT/JP2021/015546 JP2021015546W WO2021210636A1 WO 2021210636 A1 WO2021210636 A1 WO 2021210636A1 JP 2021015546 W JP2021015546 W JP 2021015546W WO 2021210636 A1 WO2021210636 A1 WO 2021210636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- therapeutic agent
- cdk4
- estrogen receptor
- agent according
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 53
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 50
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 39
- 239000012830 cancer therapeutic Substances 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims abstract description 28
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 31
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 16
- 229960002258 fulvestrant Drugs 0.000 claims description 16
- -1 2-methoxyethoxy Chemical group 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 15
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 14
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 14
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 14
- 229960004390 palbociclib Drugs 0.000 claims description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 10
- 108091008794 FGF receptors Proteins 0.000 claims description 9
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 9
- 102000015694 estrogen receptors Human genes 0.000 claims description 8
- 108010038795 estrogen receptors Proteins 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims description 7
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 7
- 229950001573 abemaciclib Drugs 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 5
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 229960001603 tamoxifen Drugs 0.000 claims description 5
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 4
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 claims description 4
- 229950009246 mepitiostane Drugs 0.000 claims description 4
- 229950003687 ribociclib Drugs 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical group Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 239000000328 estrogen antagonist Substances 0.000 abstract description 3
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000203 mixture Substances 0.000 description 15
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003890 succinate salts Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- HHHGCCLTKLPMOD-UHFFFAOYSA-N 2-methylindole-1-carboxamide Chemical compound C1=CC=C2N(C(N)=O)C(C)=CC2=C1 HHHGCCLTKLPMOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a therapeutic agent for breast cancer containing a monocyclic pyridine derivative having an FGFR inhibitory action or a pharmacologically acceptable salt thereof. More specifically, 5-((2- (4- (1- (2-hydroxyethyl) piperidine-4-yl) benzamide) pyridin-4-yl) oxy) -6- (2-methoxyethoxy) -N -For breast cancer therapeutic agents comprising methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
- Patent Document 2 It has been reported that the above compounds have a high therapeutic effect on bile duct cancer (Patent Document 2), breast cancer (Patent Document 3) and hepatocellular carcinoma (Patent Document 4). Succinate and maleate are known as pharmacologically acceptable salts of the above compounds (Patent Document 5).
- Palbociclib, abemaciclib, and the like which are cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors, are used for the treatment of estrogen receptor-positive and HER2-negative breast cancers (Non-Patent Document 1). Further, estrogen receptor antagonists such as tamoxifen and fulvestrant are used for the treatment of estrogen receptor-positive breast cancer (Non-Patent Document 2).
- Breast cancer is classified according to the presence or absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 (Human epidermal growth factor receptor Type2; HER2). Is being done.
- Non-Patent Document 3 it is known that if palbociclib and fulvestrant are continuously administered, tolerance develops and no effect is exhibited (Non-Patent Document 4).
- Bottcher et al. Acta Oncologica, 2019, 58 (2), 147-153. Howell et al., Journal of Clinical Oncology, 2004, 22 (9), 1605-1613. Seki et al., In vivo, 2019, 33, 2037-2044. Nayar et al., Nature Genetics, 2019, 51, 207-216.
- An object of the present invention is to provide a therapeutic agent for breast cancer that has developed resistance to administration of a CDK4 / 6 inhibitor and an estrogen receptor antagonist.
- the present inventors have conducted diligent studies, and as a result, the compound represented by the above formula (I) is resistant to the administration of a CDK4 / 6 inhibitor and an estrogen antagonist against breast cancer.
- the present invention has been completed by finding that it exhibits a high therapeutic effect.
- the present invention provides the following [1] to [24].
- CDK4 / 6 inhibitors and estrogen receptor antagonists including -methoxyethoxy) -N-methyl-1H-indole-1-carboxamide or pharmacologically acceptable salts thereof.
- a therapeutic agent for breast cancer that has developed resistance.
- a composition for treating breast cancer which comprises.
- a composition for treating breast cancer which comprises.
- the therapeutic agent, composition, therapeutic method, compound or use according to the above, wherein the breast cancer is negative for human epidermal growth factor receptor type 2 (HER2).
- HER2 human epidermal growth factor receptor type 2
- the estrogen receptor antagonist is at least one selected from the group consisting of tamoxifen, fulvestrant and mepitiostane.
- FGFR fibroblast growth factor receptor
- the compound represented by the formula (I) may exert a tumor volume reduction effect on breast cancer that has developed resistance to the administration of a CDK4 / 6 inhibitor and an estrogen antagonist.
- the compound represented by the formula (I) according to the present invention or a pharmacologically acceptable salt thereof can be produced by the method described in Patent Document 1.
- the pharmacologically acceptable salt includes, for example, a salt with an inorganic acid, a salt with an organic acid, a salt with an acidic amino acid, and the like.
- salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
- salts with organic acids include acetic acid, succinic acid, fumaric acid, maleic acid, tartrate acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and the like. And salt can be mentioned.
- salts with acidic amino acids include salts with aspartic acid, glutamic acid and the like.
- the preferred pharmacologically acceptable salt is succinate or maleate, and the more preferred salt is succinate.
- 1.5 succinate is preferable (hereinafter, 1.5 succinate of the compound represented by the formula (I) is referred to as compound A).
- the breast cancer therapeutic agent of the present invention can be orally administered in the form of solid preparations such as tablets, granules, fine granules, powders and capsules, or liquids, jellies and syrups.
- the breast cancer therapeutic agent of the present invention may be administered parenterally in the form of an injection, a suppository, an ointment, a poultice, or the like.
- the breast cancer therapeutic agent of the present invention can be formulated by the method described in the 17th revised Japanese Pharmacopoeia.
- the dose of the compound represented by the formula (I) or a pharmacologically acceptable salt thereof is determined by the degree of symptoms, age, sex, body weight, sensitivity difference, administration method, administration time, administration interval, pharmaceutical preparation. It can be appropriately selected according to the type and the like. Usually, when orally administered to an adult (body weight 60 kg), the daily dose is 0.5 mg to 5 g, preferably 1 mg to 1 g, and more preferably 1 mg to 500 mg. This can be administered in 1 to 3 divided doses daily.
- cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors are agents that inhibit the activities of CDK4 and CDK6, which are enzymes that are activated in cancer cells and promote disordered cell division. means.
- CDK4 / 6 inhibitor Preferable examples of the CDK4 / 6 inhibitor include palbociclib, abemaciclib, ribociclib and the like. Palbociclib is preferred.
- the dose and method of administration of the CDK4 / 6 inhibitor is, for example, in the case of palbociclib, 125 mg is orally administered once a day to an adult for 3 consecutive weeks, and then the drug is withdrawn for 1 week. With this as one cycle, administration is repeated.
- the CDK4 / 6 inhibitor is ribociclib
- the usual adult dosage is 600 mg given orally once daily for 3 consecutive weeks, followed by a 1-week rest period. With this as one cycle, administration is repeated.
- the usual adult dosage is 150 mg given orally twice daily.
- the estrogen receptor antagonist means an agent that binds to the estrogen receptor expressed in breast cancer cells. By such a mechanism, the binding between the estrogen receptor and estrogen can be inhibited, and the growth of breast cancer cells can be suppressed.
- estrogen receptor antagonist examples include tamoxifen, fulvestrant, mepitiostane and the like. Fulvestrant is preferred.
- the dose and method of administration of the estrogen receptor antagonist is, for example, in the case of fulvestrant, 500 mg is intramuscularly administered once every 4 weeks after the first 2 weeks and 4 weeks.
- estrogen receptor antagonist is tamoxifen, administer 20-40 mg orally per day.
- estrogen receptor antagonist When the estrogen receptor antagonist is mepitiostane, 20 mg per day is orally administered in two divided doses.
- an aromatase inhibitor that inhibits estrogen synthesis may be used instead of the estrogen receptor antagonist.
- the aromatase inhibitor include anastrozole, letrozole, exemestane and the like.
- breast cancer means a benign or malignant tumor that develops in the mammary gland (duct, lobules). This includes locally advanced breast cancer, metastatic breast cancer, recurrent breast cancer or unresectable breast cancer.
- Tolerance means that the effects of these agents diminish or disappear while the breast cancer patient continues to receive the CDK4 / 6 inhibitor and the estrogen receptor antagonist.
- the compound represented by the formula (I) or a pharmacologically acceptable salt thereof is administered after administration of the CDK4 / 6 inhibitor and the estrogen receptor antagonist
- CDK4 /. 6 It means that the compound represented by the formula (I) or a pharmacologically acceptable salt thereof is administered alone after developing resistance to the administration of the inhibitor and the estrogen receptor antagonist.
- Example 1 Growth inhibitory effect of compound A after administration of palbociclib and fulvestrant on tumors derived from human breast cancer patients (OD-BRE-0438) NOD-SCID mice (NOD.CB17-Prkdcscid / J, NOD.CB17-Prkdcscid / J, 5-6 patients in each group) Female, Nippon Charles River Co., Ltd.) was used to evaluate the antitumor effect of compound A after the end of the palbociclib and fulvestrant administration period.
- OD-BRE-0438 is a tumor derived from an estrogen receptor-positive breast cancer patient established by Oncodesign. The above tumor pieces were transplanted subcutaneously into mice and passaged. The tumor excised from the mouse was cut into pieces of about 4 mm square and transplanted to the subcutaneous part of the right flank of each mouse using Tracal ( ⁇ 3.5 mm).
- ⁇ -estradiol (Fujifilm Wako Pure Chemical Industries, Ltd.) was prepared in a 1 mg / mL solution with 99.5% ethanol (Fujifilm Wako Pure Chemical Industries, Ltd.). Then, the final concentration was adjusted to 2.5 ⁇ g / mL with sterilized water for water supply. Mice were allowed to ingest this freely from the day of tumor transplantation to the end of the study.
- Tumor volume (mm 3 ) major axis (mm) x minor axis (mm) x minor axis (mm) / 2
- parvocyclibuicethionate As the parvocyclibuicethionate (Selleck Chemicals), a commercially available drug substance prepared with a 50 mM sodium lactate buffer (pH 4.0) at a concentration of 10 mg / mL was used. As fulvestrant (trade name: Fesolodex intramuscular injection 250 mg, AstraZeneca Co., Ltd.), a commercially available preparation was used as it was.
- palbociclib and fulvestrant were started 26 days after tumor transplantation.
- Palbociclib was orally administered at a dose of 100 mg / kg (10 mL / kg) once daily for 14 days.
- Fulvestrant was also injected subcutaneously on days 26 and 33 at a dose of 250 mg / kg (5 mL / kg).
- mice On the 40th day, mice were grouped so that the average tumor volume of each group was almost the same.
- Compound A was dissolved in purified water to a concentration of 2.5 mg / mL. Mice in each group were orally administered Compound A at a dose of 25 mg / kg (10 mL / kg) or 50 mg / kg (20 mL / kg) once daily for 14 days. The control group was untreated.
- Tumor volume and body weight of each mouse were measured on days 3, 7, 10 and 14 days after the start of administration of Compound A.
- the changes in the average tumor volume of each group are shown in Table 1 and FIG.
- Tumor pieces were transplanted subcutaneously into mice and subcultured.
- the tumor excised from the mouse was cut into pieces of about 4 mm square and transplanted to the subcutaneous part of the right flank of each mouse using Tracal ( ⁇ 3.5 mm), which was donated to the evaluation of antitumor effect.
- ⁇ -estradiol (Fujifilm Wako Pure Chemical Industries, Ltd.) was prepared in a 1 mg / mL solution with 99.5% ethanol (Fujifilm Wako Pure Chemical Industries, Ltd.). Then, the final concentration was adjusted to 2.5 ⁇ g / mL with sterilized water for water supply. Mice were allowed to ingest this freely from the day of tumor transplantation to the end of the study.
- Compound A was dissolved in purified water to a concentration of 2.5 mg / mL. On the 32nd day after tumor transplantation, mice were grouped so that the average tumor volume of each group was almost the same. The tumor volume was calculated by the same method as in Example 1.
- mice in each group were orally administered compound A at a dose of 50 mg / kg (20 mL / kg) once a day for 14 days.
- the control group was untreated.
- Tumor volume and body weight of each mouse were measured on days 3, 7, 10 and 14 days after the start of administration of Compound A.
- the changes in the average tumor volume of each group are shown in Table 2 and FIG.
Abstract
Description
また、エストロゲン受容体拮抗剤であるタモキシフェン、フルベストラント、等は、エストロゲン受容体陽性の乳がんの治療に使用されている(非特許文献2)。
[1]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩を含む、サイクリン依存性キナーゼ4/6(CDK4/6)阻害剤およびエストロゲン受容体拮抗剤に対する耐性を生じた乳がん治療剤。
[6]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩と組み合わせて投与されることを特徴とする、CDK4/6阻害剤およびエストロゲン受容体拮抗剤を含む、乳がん治療用組成物。
[7]CDK4/6阻害剤およびエストロゲン受容体拮抗剤と組み合わせて投与されることを特徴とする、式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩を含む、乳がん治療用組成物。
[8]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩が、CDK4/6阻害剤およびエストロゲン受容体拮抗剤の投与後に投与される、[6]または[7]に記載の組成物。
[10]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩、CDK4/6阻害剤およびエストロゲン受容体拮抗剤を、それらを必要とする患者に投与することを含む、乳がんの治療方法。
[11]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩を、CDK4/6阻害剤およびエストロゲン受容体拮抗剤の投与後に、それを必要とする患者に投与することを含む、[10]に記載の治療方法。
[13]CDK4/6阻害剤およびエストロゲン受容体拮抗剤に対する耐性を生じた乳がん治療剤の製造ための、式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬理学的に許容される塩の使用。
[15]乳がんがCDK4/6阻害剤およびエストロゲン受容体拮抗剤に対する耐性を生じた乳がんである、上記記載の治療剤、組成物、治療方法、化合物または使用。
[16]乳がんがエストロゲン受容体陽性である、上記記載の治療剤、組成物、治療方法、化合物または使用。
[17]乳がんがヒト上皮成長因子受容体タイプ2(HER2)陰性である、上記記載の治療剤、組成物、治療方法、化合物または使用。
[18]CDK4/6阻害剤がパルボシクリブ、アベマシクリブおよびリボシクリブからなる群から選ばれる1種以上である、上記記載の治療剤、組成物、治療方法、化合物または使用。
[19]CDK4/6阻害剤がパルボシクリブである、上記記載の治療剤、組成物、治療方法、化合物または使用。
[20]エストロゲン受容体拮抗剤がタモキシフェン、フルベストラントおよびメピチオスタンからなる群から選ばれる1種以上である、上記記載の治療剤、組成物、治療方法、化合物または使用。
[21]エストロゲン受容体拮抗剤がフルベストラントである、上記記載の治療剤、組成物、治療方法、化合物または使用。
[22]乳がんが局所進行乳がん、転移乳がん、再発乳がんまたは切除不能な乳がんである、上記記載の治療剤、組成物、治療方法、化合物または使用。
[23]乳がんが線維芽細胞増殖因子受容体(FGFR)を発現しているものである、上記記載の治療剤、組成物、治療方法、化合物または使用。
[24]FGFRがFGFR1、FGFR2またはFGFR3である、上記記載の治療剤、組成物、治療方法、化合物または使用。
各群5-6例のNOD-SCIDマウス(NOD.CB17-Prkdcscid/J、雌、日本チャールズ・リバー株式会社)を使用して、パルボシクリブおよびフルベストラント投与期間終了後に、化合物Aを投与した場合の抗腫瘍効果を評価した。
腫瘍体積(mm3)=長径(mm)×短径(mm)×短径(mm)/2
各群のマウスに、化合物Aを25mg/kg(10mL/kg)または50mg/kg(20mL/kg)の用量で、1日1回、14日間、経口投与した。対照群は無処置とした。
各群6例のNOD-SCIDマウス(NOD.CB17-Prkdcscid/J、雌、日本チャールズ・リバー株式会社)を使用して、化合物Aを投与した場合の抗腫瘍効果を評価した。
腫瘍移植後32日に、各群の腫瘍体積平均値がほぼ同じとなるように、マウスの群分けを行った。なお、実施例1と同様の方法で腫瘍体積を算出した。
Claims (15)
- 乳がんがCDK4/6阻害剤およびエストロゲン受容体拮抗剤に対する耐性を生じた乳がんである、請求項2~4のいずれか一項に記載の治療剤。
- 薬理学的に許容される塩が1.5コハク酸塩である、請求項1~5のいずれか一項に記載の治療剤。
- 乳がんがエストロゲン受容体陽性である、請求項1~6のいずれか一項に記載の治療剤。
- 乳がんがヒト上皮成長因子受容体タイプ2(HER2)陰性である、請求項1~7のいずれか一項に記載の治療剤。
- CDK4/6阻害剤がパルボシクリブ、アベマシクリブおよびリボシクリブからなる群から選ばれる1種以上である、請求項1~8のいずれか一項に記載の治療剤。
- CDK4/6阻害剤がパルボシクリブである、請求項9に記載の治療剤。
- エストロゲン受容体拮抗剤がタモキシフェン、フルベストラントおよびメピチオスタンからなる群から選ばれる1種以上である、請求項1~10のいずれか一項に記載の治療剤。
- エストロゲン受容体拮抗剤がフルベストラントである、請求項11に記載の治療剤。
- 乳がんが局所進行乳がん、転移乳がん、再発乳がんまたは切除不能な乳がんである、請求項1~12のいずれか一項に記載の治療剤。
- 乳がんが線維芽細胞増殖因子受容体(FGFR)を発現しているものである、請求項1~13のいずれか一項に記載の治療剤。
- FGFRがFGFR1、FGFR2またはFGFR3である、請求項14に記載の治療剤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3180128A CA3180128A1 (en) | 2020-04-17 | 2021-04-15 | Breast cancer therapeutic agent |
JP2022515429A JPWO2021210636A1 (ja) | 2020-04-17 | 2021-04-15 | |
MX2022012934A MX2022012934A (es) | 2020-04-17 | 2021-04-15 | Agente terapeutico para cancer de mama. |
CN202180028460.3A CN115397415A (zh) | 2020-04-17 | 2021-04-15 | 乳腺癌治疗剂 |
US17/918,829 US20230149381A1 (en) | 2020-04-17 | 2021-04-15 | Breast cancer therapeutic agent |
BR112022020786A BR112022020786A2 (pt) | 2020-04-17 | 2021-04-15 | Agente terapêutico de câncer de mama |
AU2021255084A AU2021255084A1 (en) | 2020-04-17 | 2021-04-15 | Breast cancer therapeutic agent |
KR1020227039422A KR20230004595A (ko) | 2020-04-17 | 2021-04-15 | 유방암 치료제 |
EP21787967.5A EP4122465A4 (en) | 2020-04-17 | 2021-04-15 | THERAPEUTIC AGENT AGAINST BREAST CANCER |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-074386 | 2020-04-17 | ||
JP2020074386 | 2020-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021210636A1 true WO2021210636A1 (ja) | 2021-10-21 |
Family
ID=78084563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/015546 WO2021210636A1 (ja) | 2020-04-17 | 2021-04-15 | 乳がん治療剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230149381A1 (ja) |
EP (1) | EP4122465A4 (ja) |
JP (1) | JPWO2021210636A1 (ja) |
KR (1) | KR20230004595A (ja) |
CN (1) | CN115397415A (ja) |
AU (1) | AU2021255084A1 (ja) |
BR (1) | BR112022020786A2 (ja) |
CA (1) | CA3180128A1 (ja) |
MX (1) | MX2022012934A (ja) |
WO (1) | WO2021210636A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4151212A4 (en) * | 2020-07-31 | 2024-04-10 | Eisai R&D Man Co Ltd | THERAPEUTIC AGENT AGAINST BREAST CANCER |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140235614A1 (en) | 2013-02-20 | 2014-08-21 | Eisai R&D Management Co., Ltd. | Monocyclic pyridine derivative |
WO2017104739A1 (ja) * | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
US20170217935A1 (en) | 2014-08-18 | 2017-08-03 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
US20180015079A1 (en) | 2015-03-25 | 2018-01-18 | National Cancer Center | Therapeutic agent for bile duct cancer |
WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014235614A (ja) | 2013-06-03 | 2014-12-15 | 株式会社ゼネット | 総合学習支援ネットワークシステム及び総合学習支援方法 |
JP2017217935A (ja) | 2016-06-03 | 2017-12-14 | 株式会社東海理化電機製作所 | ステアリングスイッチ装置 |
JP2018022750A (ja) | 2016-08-02 | 2018-02-08 | 太陽誘電株式会社 | 積層セラミックコンデンサ |
CN110022900A (zh) * | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
-
2021
- 2021-04-15 CA CA3180128A patent/CA3180128A1/en active Pending
- 2021-04-15 EP EP21787967.5A patent/EP4122465A4/en active Pending
- 2021-04-15 JP JP2022515429A patent/JPWO2021210636A1/ja active Pending
- 2021-04-15 BR BR112022020786A patent/BR112022020786A2/pt unknown
- 2021-04-15 KR KR1020227039422A patent/KR20230004595A/ko unknown
- 2021-04-15 MX MX2022012934A patent/MX2022012934A/es unknown
- 2021-04-15 WO PCT/JP2021/015546 patent/WO2021210636A1/ja unknown
- 2021-04-15 US US17/918,829 patent/US20230149381A1/en active Pending
- 2021-04-15 CN CN202180028460.3A patent/CN115397415A/zh active Pending
- 2021-04-15 AU AU2021255084A patent/AU2021255084A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140235614A1 (en) | 2013-02-20 | 2014-08-21 | Eisai R&D Management Co., Ltd. | Monocyclic pyridine derivative |
US20170217935A1 (en) | 2014-08-18 | 2017-08-03 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
US20180015079A1 (en) | 2015-03-25 | 2018-01-18 | National Cancer Center | Therapeutic agent for bile duct cancer |
WO2017104739A1 (ja) * | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
US20180303817A1 (en) | 2015-12-17 | 2018-10-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
Non-Patent Citations (7)
Title |
---|
BOTTCHER ET AL., ACTA ONCOLOGICA, vol. 58, no. 2, 2019, pages 147 - 153 |
FORMISANO, LUIGI ET AL.: "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer", NATURE COMMUNICATIONS, vol. 10, no. 1373, 2019, pages 1 - 14, XP055867436, DOI: https://doi.org/10.1038/s41467-019-09068-2 * |
HOWELL ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 9, 2004, pages 1605 - 1613 |
JAPANESE PHARMACOPOEIA |
NAYAR ET AL., NATURE GENETICS, vol. 51, 2019, pages 207 - 216 |
See also references of EP4122465A4 |
SEKI ET AL., IN VIVO, vol. 33, 2019, pages 2037 - 2044 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4151212A4 (en) * | 2020-07-31 | 2024-04-10 | Eisai R&D Man Co Ltd | THERAPEUTIC AGENT AGAINST BREAST CANCER |
Also Published As
Publication number | Publication date |
---|---|
US20230149381A1 (en) | 2023-05-18 |
JPWO2021210636A1 (ja) | 2021-10-21 |
KR20230004595A (ko) | 2023-01-06 |
BR112022020786A2 (pt) | 2022-11-29 |
CN115397415A (zh) | 2022-11-25 |
AU2021255084A1 (en) | 2022-12-08 |
EP4122465A1 (en) | 2023-01-25 |
EP4122465A4 (en) | 2024-03-20 |
CA3180128A1 (en) | 2021-10-21 |
MX2022012934A (es) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
AU2015278765B2 (en) | Intermittent dosing of MDM2 inhibitor | |
US20160051525A1 (en) | Combination therapy for proliferative disorders | |
US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
AU2019263026B2 (en) | Combinations for treating cancer | |
EP3027191A1 (en) | Combinations of a btk inhibitor and fluorouracil for treating cancers | |
JP2023515817A (ja) | ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ | |
WO2021210636A1 (ja) | 乳がん治療剤 | |
AU2017235346B2 (en) | Combination therapy for proliferative diseases | |
US7879868B2 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents | |
US20190125751A1 (en) | Anticancer combination therapy | |
TW202402290A (zh) | 癌症治療 | |
CN117177752A (zh) | 用于治疗mpnst的化合物和组合物 | |
WO2021104341A1 (zh) | 一种取代丁烯酰胺的应用 | |
WO2022025150A1 (ja) | 乳がん治療剤 | |
TW201806601A (zh) | σ受體配體在皰疹後遺疼痛中的用途 | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
JP6714225B2 (ja) | 肝細胞癌の予防又は治療のための医薬 | |
WO2020045461A1 (ja) | ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤 | |
WO2012026511A1 (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21787967 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022515429 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3180128 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022020786 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021787967 Country of ref document: EP Effective date: 20221018 |
|
ENP | Entry into the national phase |
Ref document number: 20227039422 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022020786 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221013 |
|
ENP | Entry into the national phase |
Ref document number: 2021255084 Country of ref document: AU Date of ref document: 20210415 Kind code of ref document: A |